During a live Community Case Forum event in partnership with the Tennessee Oncology Practice Society, Pierre Gholam, MD, ...

Targeted therapies and immunotherapies across the ovarian, endometrial, and cervical cancers landscape play expanded roles, ...

During a Case-Based Roundtable® event, Stanley M. Marks, MD, moderated a discussion on the impact of cardiac adverse events ...

Chavez, MD, discusses the potential of tarlatamab and its use in the frontline setting for the treatment of patients with ...

In a retrospective study in patients with hepatocellular carcinoma, 40% of patients developed irAEs after receiving the first ...

In an interview with Targeted Oncology, Ben Jones identified the key challenges community oncologists are facing due to ...

In an interview with Targeted Oncology for Head and Neck Cancer Awareness Month, Noel Laudi, MD, MRCP, discussed the link ...

Sanjay K. Juneja, MD, Targeted Oncology’s first 2024 Oncology Icon, delves into his background and what drove him to pursue a ...

Following its recent FDA approval in non-muscle-invasive bladder cancer, nogapendekin alfa has also shown overall survival ...

With the approval of belzutifan and other newer data for treating patients with recurrent renal cell carcinoma, the state of ...

In the interview with Targeted Oncology, Sanjay K. Juneja, MD, 2024 Oncology Icons honoree, discusses the transformative ...

John M. Burke, MD, discusses results from a phase 2 study which evaluated brentuximab vedotin, nivolumab, doxorubicin, and ...